Articles
12 June 2009
Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
https://doi.org/10.4081/hmr.v3i3.566

Brazilian experience using high dose sequential followed by autologous hematopoietic stem cell transplantation for malignant lymphomas

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
218
Views
153
Downloads

Authors

BKL Duarte
support@pagepress.org
AC Vigorito
FJP Aranha
R Baldissera
ECM Miranda
IL Lorand-Metze
KB Pagnano
CA De Souza
The therapeutic of malignant lymphomas has undergone several advances through the last decades. Despite these advances, the management of relapsed and resistant patients with malignant lymphomas using conventional chemotherapy is disappointing. While patients with Hodgkin’s lymphoma (HL) have a favorable outcome when treated with regimens such as ABVD, MOPPABV and BEACOPP, with complete remission (CR) rates as high as 95%, and cure rates of 60- 85%.1,2 Some patients with advanced disease and poor prognostic factors have a poor outcome, with disease free survival (DFS) of about 10%.3-5

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Brazilian experience using high dose sequential followed by autologous hematopoietic stem cell transplantation for malignant lymphomas. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.566